For laboratory research use only. Not for human or veterinary use. Read our research-use policy

Laboratory practice

Peptide purity vs peptide content: a mass balance of the vial

A purity percentage and a peptide content percentage describe different things. This page works through where the mass of a lyophilised vial goes, and estimates counter-ion mass from the sequence for thirteen peptides.

Published 19 November 2026 · Last updated 19 November 2026

Two questions, two numbers

Purity asks: of the peptide-related material in this powder, how much is the target sequence? It is measured by reversed-phase HPLC as a UV peak-area fraction (see peptide purity: HPLC and mass spectrometry). Peptide content asks: how much of the powder is peptide at all? It is not visible on a chromatogram, because counter-ions such as trifluoroacetate (TFA) and water do not absorb at the detection wavelength used for the peptide bond. The companion articles on net peptide content and counter-ions define the terms; this one puts numbers on them.

The reason this matters in practice is concentration. A solution made by dissolving the labelled amount of powder contains less peptide than the label implies, by the share of the powder that is counter-ion and water. Purity then removes a further, usually smaller, fraction.

Where the counter-ion comes from

Synthetic peptides made by solid-phase synthesis are cleaved from the resin with TFA and purified with TFA as an ion-pairing agent, so they are obtained as TFA salts (Erckes et al., 2025). The positive charges on the peptide, which sit on the free N-terminus and on lysine and arginine side chains, hold the trifluoroacetate anions. Erckes et al. used detected counter-ion contents to examine how sequence differences, especially positive charges, affect the amount of counter-ion, and describe replacing TFA with chloride by freeze-drying from dilute HCl.

That gives a simple structural estimate. Count the basic sites, assume one counter-ion each, and the counter-ion mass follows from arithmetic:

  • Counter-ion mass = number of basic sites × counter-ion mass (TFA: 114.02 g/mol; acetic acid: 60.05 g/mol)
  • Peptide share of the dry salt = peptide MW ÷ (peptide MW + counter-ion mass)

The estimate for thirteen peptides

Peptide masses are the PubChem values on each compound page. The basic-site count is the free N-terminus (absent when the peptide is N-acetylated or starts with pyroglutamate) plus every lysine and arginine in the sequence. Histidine, which is only partly protonated near neutral pH, is not counted.

Peptide fraction of the dry salt if every counted basic site carries one counter-ion (a ceiling model, not a measurement)
PeptidePeptide MW (g/mol)Lys + Arg + free N-terminusTFA mass added (g/mol)Peptide share, TFA saltPeptide share, acetate salt
KPV342.41 + 0 + 1 = 2228.060.0%74.0%
Epithalon390.40 + 0 + 1 = 1114.077.4%86.7%
DSIP848.80 + 0 + 1 = 1114.088.2%93.4%
Semax813.90 + 0 + 1 = 1114.087.7%93.1%
ARA-2901257.30 + 1 + 0 = 1114.091.7%95.4%
Kisspeptin-101302.40 + 1 + 1 = 2228.085.1%91.6%
BPC-1571419.51 + 0 + 1 = 2228.086.2%92.2%
Selank751.91 + 1 + 1 = 3342.168.7%80.7%
Melanotan II1024.21 + 1 + 0 = 2228.081.8%89.5%
MOTS-c2174.61 + 3 + 1 = 5570.179.2%87.9%
Humanin2687.01 + 3 + 1 = 5570.182.5%89.9%
Thymosin alpha-13108.04 + 0 + 0 = 4456.187.2%92.8%
LL-374493.06 + 5 + 1 = 121368.376.7%86.2%

Two patterns follow from the arithmetic. The share depends on the number of basic sites relative to the peptide's mass, so the shortest peptides with a lysine or arginine, such as the tripeptide KPV (two sites on 342.4 g/mol) and the heptapeptide Selank (three sites on 751.9 g/mol), have the lowest peptide share in the table. Peptides with a single site on a larger mass, such as ARA-290, DSIP and Semax, have the highest. A longer peptide is not automatically safer: LL-37 has twelve counted sites, and its larger mass only partly offsets them. A peptide with several acidic residues may also hold fewer counter-ions than the count suggests, because acidic side chains compensate some of the charge; that effect is not modelled here.

Treat the table as a ceiling-style estimate under one stated assumption, not as a statement about any product. A supplier that has exchanged the counter-ion, or a sequence with unusual pairing, will give a different value, and water comes on top.

A worked mass balance

The values below are hypothetical, chosen to show the arithmetic: a 5.00 mg vial of a BPC-157 TFA salt, 5% water and 98% HPLC purity. The counter-ion mass comes from the table above (two basic sites).

Hypothetical 5.00 mg vial of a BPC-157 TFA salt: where the mass goes (assumed water 5% and HPLC purity 98%)
ComponentHow it is obtainedMass (mg)Share of gross
Gross powderFill weight on the label5.00100.0%
WaterAssumed 5% of gross (a real value comes from Karl Fischer titration)0.255.0%
TrifluoroacetateDry mass × 228.0 ÷ (1419.5 + 228.0)0.6613.1%
All peptidic materialDry mass × 1419.5 ÷ (1419.5 + 228.0); this is the net peptide content4.0981.9%
Peptide-related impurities(1 − 0.98) × peptidic material0.081.6%
Target sequence0.98 × peptidic material4.0180.2%

The vial label says 5 mg, and the target sequence is about 4.01 mg of it. Both numbers, 98% purity and 80.2% of the gross weight, are true at once. The consequence for concentration: if the whole 5.00 mg were peptide, the vial would hold 3.52 µmol; the target sequence is about 2.83 µmol, so a solution calculated from the label would contain about 20% less of the target peptide than the label arithmetic gives. The reconstitution calculator works from the stated amount; apply a correction from the batch's measured content if you need an exact molarity.

What the estimate leaves out

  • Water. Lyophilised peptides take up moisture, and water content has to be measured (for example by Karl Fischer titration). The 5% above is an assumption.
  • Counter-ion stoichiometry. Real batches can carry fewer or more counter-ions than the number of basic sites, and free acid can remain. Erckes et al. (2025) validated FT-IR, 19F-NMR and HPLC with an evaporative light-scattering detector for quantifying residual TFA.
  • Other residues. Inorganic salts, residual solvents and other synthesis by-products add mass that neither purity nor this estimate captures.

How reference laboratories do it

McCarthy et al. (2023) describe a mass-balance approach for assigning a quantitative value to a bulk peptide material, then using that material as a standard to value the vialed material, with NMR, mass spectrometry and chromatographic methods for identity, and HPLC and gas chromatography methods for peptide content and impurities. Reviews of peptide characterisation for regulatory purposes stress using several orthogonal methods rather than one (Kuril et al., 2024; Wu et al., 2017). For a research purchase the practical version is a checklist of what a batch document states:

  • HPLC purity, with the wavelength and method named.
  • Identity by mass spectrometry (how to check it yourself).
  • Net peptide content, and how it was measured (amino acid analysis or nitrogen analysis).
  • Counter-ion identity and content, and water content.

Where a document leaves net peptide content out, record that the concentration you calculate is nominal. Our product pages show stated purity labelled as supplier-stated and mark the batch COA as not yet provided until one exists. See how to read a peptide Certificate of Analysis for the full list.

Related: how the counter-ion is exchanged and verified, and what it does to these percentages, and how to read the chromatogram behind a purity figure.

References

  1. McCarthy D, Han Y, Carrick K, et al. (2023). Reference Standards to Support Quality of Synthetic Peptide Therapeutics. Pharm Res 40:1317-1328. PubMed 36949371 · DOI
  2. Erckes V, Streuli A, Chamera Rendueles L, et al. (2025). Towards a Consensus for the Analysis and Exchange of TFA as a Counterion in Synthetic Peptides and Its Influence on Membrane Permeation. Pharmaceuticals (Basel) 18. PubMed 40872554 · DOI
  3. Kuril AK, Saravanan K, Subbappa PK (2024). Analytical considerations for characterization of generic peptide product: A regulatory insight. Anal Biochem 694:115633. PubMed 39089363 · DOI
  4. Wu LC, Chen F, Lee SL, et al. (2017). Building parity between brand and generic peptide products: Regulatory and scientific considerations for quality of synthetic peptides. Int J Pharm 518:320-334. PubMed 28027918 · DOI
  5. PubChem compound records, pubchem.ncbi.nlm.nih.gov: peptide molecular weights (the CIDs are on each compound page), trifluoroacetic acid (C2HF3O2) and acetic acid (C2H4O2) formulas; masses computed here with standard atomic weights.

Frequently asked questions

Is 98% HPLC purity the same as 98% peptide?

No. HPLC purity is the share of the peptide-related UV signal that belongs to the target sequence. Peptide content is the share of the powder that is peptide at all; counter-ions and water make up the rest. A powder can be 98% pure and still contain well under 90% peptide by weight.

Why is there less peptide in a vial than the label amount?

The label amount is usually the gross powder weight. Synthetic peptides are supplied as salts (commonly trifluoroacetate) with bound water, so part of that weight is counter-ion and water.

Can I estimate the counter-ion mass from the sequence?

Roughly. Each basic site (the free N-terminus, lysine and arginine) can pair with one counter-ion. Dividing the peptide mass by the peptide-plus-counter-ion mass gives a ceiling-style estimate, shown in the table on this page. Only a measurement of the batch gives the real value.

How is peptide content measured?

Common methods are amino acid analysis and nitrogen analysis for peptide content, with counter-ion content measured separately (for example by ion chromatography, 19F-NMR or FT-IR for TFA) and water by Karl Fischer titration. Reference laboratories combine them in a mass balance.